Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Follow-Up Questions
Immunovant Inc 'in CEO'su kimdir?
Dr. Eric Venker 2020 'den beri şirketle birlikte olan Immunovant Inc 'in Chief Executive Officer 'ıdır.
IMVT hissesinin fiyat performansı nasıl?
IMVT 'in mevcut fiyatı $25.21 'dir, son işlem günde 2.15% increased etti.
Immunovant Inc için ana iş temaları veya sektörler nelerdir?
Immunovant Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Immunovant Inc 'in piyasa değerlemesi nedir?
Immunovant Inc 'in mevcut piyasa değerlemesi $4.3B 'dir
Immunovant Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 16 analist Immunovant Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 8 güçlü al, 9 al, 5 tut, 0 sat ve 8 güçlü sat içermektedir
